Benington, United Kingdom

Simon John MacDonald

This inventor holds 2 USPTO granted patents. Top assignee: Glaxo Wellcome Inc.. Active years: 1999-2000.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Simon John MacDonald. Retrieved from https://idiyas.com/inventor/simon-john-macdonald

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

Average Co-Inventor Count = 4.4

ph-index = 1

Forward Citations = 4(Granted Patents)


Company Filing History:


Years Active: 1999-2000

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Innovations by Simon John MacDonald

Introduction

Simon John MacDonald is a notable inventor based in Benington, GB. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that have therapeutic applications.

Latest Patents

MacDonald holds two patents, with his latest focusing on pyrrolopyrrolone derivatives as inhibitors of neutrophil elastase. These compounds, described by the formula (XXII).sup.a, are useful as intermediates in the production of pharmaceuticals aimed at treating chronic bronchitis.

Career Highlights

He is associated with Glaxo Wellcome Inc., a prominent company in the pharmaceutical industry. His work has contributed to advancements in medical treatments and has the potential to improve the quality of life for patients suffering from respiratory conditions.

Collaborations

MacDonald has collaborated with notable colleagues, including Michael D Dowle and Harry Finch, enhancing the innovative capacity of his projects.

Conclusion

Simon John MacDonald exemplifies the spirit of innovation in the pharmaceutical sector, with his patents paving the way for new treatments in chronic bronchitis.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…